🇺🇸 FDA

Drug profile · INN

mirvetuximab soravtansine-gynx

ELAHERE

approved
US status
approved
Patents linked
0
News articles
1

Quick answer

mirvetuximab soravtansine-gynx (ELAHERE) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN mirvetuximab soravtansine-gynx
Brand ELAHERE
Route INJECTION
Formulation INJECTABLE

Frequently asked questions

What is mirvetuximab soravtansine-gynx?

mirvetuximab soravtansine-gynx (ELAHERE) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for mirvetuximab soravtansine-gynx?

ELAHERE is a marketed brand name for mirvetuximab soravtansine-gynx. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of mirvetuximab soravtansine-gynx?

mirvetuximab soravtansine-gynx has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.